Cargando…
The challenge of developmental therapeutics for adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of only 0.7 new cases per million per year. Approximately 30-70% of the patients present with advanced disease with very poor prognosis and without effective therapeutic options. In the recent years, unprecedented progresse...
Autores principales: | Costa, Ricardo, Carneiro, Benedito A., Tavora, Fabio, Pai, Sachin G., Kaplan, Jason B., Chae, Young Kwang, Chandra, Sunandana, Kopp, Peter A., Giles, Francis J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216833/ https://www.ncbi.nlm.nih.gov/pubmed/27102148 http://dx.doi.org/10.18632/oncotarget.8774 |
Ejemplares similares
-
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
por: Costa, Ricardo, et al.
Publicado: (2016) -
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
por: Chuzi, Sarah, et al.
Publicado: (2017) -
FGFR3-TACC3 fusion in solid tumors: mini review
por: Costa, Ricardo, et al.
Publicado: (2016) -
Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling
por: Chae, Young Kwang, et al.
Publicado: (2015) -
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
por: Chae, Young Kwang, et al.
Publicado: (2016)